MX2020009246A - Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. - Google Patents
Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.Info
- Publication number
- MX2020009246A MX2020009246A MX2020009246A MX2020009246A MX2020009246A MX 2020009246 A MX2020009246 A MX 2020009246A MX 2020009246 A MX2020009246 A MX 2020009246A MX 2020009246 A MX2020009246 A MX 2020009246A MX 2020009246 A MX2020009246 A MX 2020009246A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- cardiovascular risk
- methods
- pcsk9 inhibitor
- risk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639407P | 2018-03-06 | 2018-03-06 | |
| US201862640361P | 2018-03-08 | 2018-03-08 | |
| US201862641082P | 2018-03-09 | 2018-03-09 | |
| US201862641918P | 2018-03-12 | 2018-03-12 | |
| US201862657495P | 2018-04-13 | 2018-04-13 | |
| US201862683695P | 2018-06-12 | 2018-06-12 | |
| US201862688622P | 2018-06-22 | 2018-06-22 | |
| US201862717530P | 2018-08-10 | 2018-08-10 | |
| US201862736284P | 2018-09-25 | 2018-09-25 | |
| US201862744008P | 2018-10-10 | 2018-10-10 | |
| US201862746319P | 2018-10-16 | 2018-10-16 | |
| US201862770530P | 2018-11-21 | 2018-11-21 | |
| US201862775219P | 2018-12-04 | 2018-12-04 | |
| US201962797680P | 2019-01-28 | 2019-01-28 | |
| US201962802545P | 2019-02-07 | 2019-02-07 | |
| US201962806313P | 2019-02-15 | 2019-02-15 | |
| EP19305247 | 2019-03-04 | ||
| PCT/US2019/021034 WO2019173530A1 (en) | 2018-03-06 | 2019-03-06 | Use of pcsk9 inhibitor for reducing cardiovascular risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009246A true MX2020009246A (es) | 2021-01-15 |
Family
ID=66001316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009246A MX2020009246A (es) | 2018-03-06 | 2019-03-06 | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190292273A1 (https=) |
| EP (1) | EP3762026B1 (https=) |
| JP (2) | JP7426940B2 (https=) |
| KR (1) | KR20200129127A (https=) |
| CN (1) | CN113015543A (https=) |
| AU (1) | AU2019231703A1 (https=) |
| CA (1) | CA3092936A1 (https=) |
| IL (1) | IL277127B2 (https=) |
| MX (1) | MX2020009246A (https=) |
| TW (2) | TW201945401A (https=) |
| WO (1) | WO2019173530A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9402707B2 (en) | 2008-07-22 | 2016-08-02 | Neuravi Limited | Clot capture systems and associated methods |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| WO2012052982A1 (en) | 2010-10-22 | 2012-04-26 | Neuravi Limited | Clot engagement and removal system |
| PL3395836T3 (pl) | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
| ES3029850T3 (en) | 2011-03-09 | 2025-06-25 | Neuravi Ltd | A clot retrieval device for removing occlusive clot from a blood vessel |
| US12076037B2 (en) | 2011-03-09 | 2024-09-03 | Neuravi Limited | Systems and methods to restore perfusion to a vessel |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| US9433429B2 (en) | 2013-03-14 | 2016-09-06 | Neuravi Limited | Clot retrieval devices |
| SI2967610T1 (sl) | 2013-03-14 | 2019-07-31 | Neuravi Limited | Naprava za odkrivanje strdka za odstranjevanje okluzivnega strdka in krvne žile |
| EP2967611B1 (en) | 2013-03-14 | 2019-01-16 | Neuravi Limited | Devices for removal of acute blockages from blood vessels |
| MX2016006226A (es) | 2013-11-12 | 2016-09-07 | Sanofi Biotechnology | Regimenes de dosificacion para uso con inhibidores de pcsk9. |
| US11253278B2 (en) | 2014-11-26 | 2022-02-22 | Neuravi Limited | Clot retrieval system for removing occlusive clot from a blood vessel |
| EP3223723B1 (en) | 2014-11-26 | 2020-01-08 | Neuravi Limited | A clot retrieval device for removing occlusive clot from a blood vessel |
| US10617435B2 (en) | 2014-11-26 | 2020-04-14 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| KR102494176B1 (ko) | 2016-09-06 | 2023-02-02 | 뉴라비 리미티드 | 혈관으로부터 폐색 혈전을 제거하기 위한 혈전 회수 장치 |
| US10842498B2 (en) * | 2018-09-13 | 2020-11-24 | Neuravi Limited | Systems and methods of restoring perfusion to a vessel |
| US11406416B2 (en) | 2018-10-02 | 2022-08-09 | Neuravi Limited | Joint assembly for vasculature obstruction capture device |
| TWI759867B (zh) * | 2019-09-19 | 2022-04-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗前蛋白轉化酶枯草桿菌蛋白酶／ｋｅｘｉｎ型９抗體用於製備治療膽固醇相關疾病之藥物的用途 |
| US11712231B2 (en) | 2019-10-29 | 2023-08-01 | Neuravi Limited | Proximal locking assembly design for dual stent mechanical thrombectomy device |
| US11517340B2 (en) | 2019-12-03 | 2022-12-06 | Neuravi Limited | Stentriever devices for removing an occlusive clot from a vessel and methods thereof |
| US11717308B2 (en) | 2020-04-17 | 2023-08-08 | Neuravi Limited | Clot retrieval device for removing heterogeneous clots from a blood vessel |
| US11871946B2 (en) | 2020-04-17 | 2024-01-16 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
| US11730501B2 (en) | 2020-04-17 | 2023-08-22 | Neuravi Limited | Floating clot retrieval device for removing clots from a blood vessel |
| US11737771B2 (en) | 2020-06-18 | 2023-08-29 | Neuravi Limited | Dual channel thrombectomy device |
| US11937836B2 (en) | 2020-06-22 | 2024-03-26 | Neuravi Limited | Clot retrieval system with expandable clot engaging framework |
| US11439418B2 (en) | 2020-06-23 | 2022-09-13 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
| US11395669B2 (en) | 2020-06-23 | 2022-07-26 | Neuravi Limited | Clot retrieval device with flexible collapsible frame |
| US11864781B2 (en) | 2020-09-23 | 2024-01-09 | Neuravi Limited | Rotating frame thrombectomy device |
| US11937837B2 (en) | 2020-12-29 | 2024-03-26 | Neuravi Limited | Fibrin rich / soft clot mechanical thrombectomy device |
| US12029442B2 (en) | 2021-01-14 | 2024-07-09 | Neuravi Limited | Systems and methods for a dual elongated member clot retrieval apparatus |
| US12064130B2 (en) | 2021-03-18 | 2024-08-20 | Neuravi Limited | Vascular obstruction retrieval device having sliding cages pinch mechanism |
| US11974764B2 (en) | 2021-06-04 | 2024-05-07 | Neuravi Limited | Self-orienting rotating stentriever pinching cells |
| CN115413625A (zh) * | 2022-08-22 | 2022-12-02 | 郑咏秋 | 一种类风湿性冠心病动物模型及其构建方法和应用 |
| CN118116596B (zh) * | 2024-04-25 | 2024-07-02 | 青岛宝迈得生物科技有限公司 | 基于大数据分析的肝胆与心血管疾病共发风险评估方法 |
| CN121015868B (zh) * | 2025-10-29 | 2026-03-20 | 核工业四一六医院 | Pcsk9抑制剂在制备用于治疗甲减伴高脂血症的药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| PL3395836T3 (pl) | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2992345T3 (es) | 2011-09-16 | 2024-12-11 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| NZ727849A (en) * | 2012-06-29 | 2018-06-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| KR20220048051A (ko) * | 2013-10-11 | 2022-04-19 | 사노피 바이오테크놀로지 | 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도 |
| AU2015231713B2 (en) * | 2014-03-17 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Methods for reducing cardiovascular risk |
| RU2723018C2 (ru) | 2014-07-16 | 2020-06-08 | Санофи Байотекнолоджи | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию |
| JP2018523684A (ja) * | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
-
2019
- 2019-03-06 CA CA3092936A patent/CA3092936A1/en active Pending
- 2019-03-06 JP JP2020546481A patent/JP7426940B2/ja active Active
- 2019-03-06 TW TW108107481A patent/TW201945401A/zh unknown
- 2019-03-06 WO PCT/US2019/021034 patent/WO2019173530A1/en not_active Ceased
- 2019-03-06 CN CN201980029013.2A patent/CN113015543A/zh active Pending
- 2019-03-06 EP EP19715280.4A patent/EP3762026B1/en active Active
- 2019-03-06 AU AU2019231703A patent/AU2019231703A1/en not_active Abandoned
- 2019-03-06 US US16/294,635 patent/US20190292273A1/en not_active Abandoned
- 2019-03-06 IL IL277127A patent/IL277127B2/en unknown
- 2019-03-06 TW TW113130634A patent/TW202521589A/zh unknown
- 2019-03-06 MX MX2020009246A patent/MX2020009246A/es unknown
- 2019-03-06 KR KR1020207028410A patent/KR20200129127A/ko not_active Ceased
-
2023
- 2023-12-08 JP JP2023207363A patent/JP2024028919A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024028919A (ja) | 2024-03-05 |
| KR20200129127A (ko) | 2020-11-17 |
| EP3762026A1 (en) | 2021-01-13 |
| WO2019173530A1 (en) | 2019-09-12 |
| IL277127B1 (en) | 2025-07-01 |
| CA3092936A1 (en) | 2019-09-12 |
| TW202521589A (zh) | 2025-06-01 |
| US20190292273A1 (en) | 2019-09-26 |
| RU2020132463A (ru) | 2022-04-06 |
| IL277127B2 (en) | 2025-11-01 |
| TW201945401A (zh) | 2019-12-01 |
| IL277127A (en) | 2020-10-29 |
| JP7426940B2 (ja) | 2024-02-02 |
| AU2019231703A1 (en) | 2020-10-22 |
| JP2021515772A (ja) | 2021-06-24 |
| EP3762026B1 (en) | 2026-04-08 |
| CN113015543A (zh) | 2021-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009246A (es) | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. | |
| MX380767B (es) | Métodos para reducir el riesgo cardiovascular. | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| BR112022010349A2 (pt) | Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma | |
| MX379286B (es) | INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe). | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| Imbernon‐Moya et al. | Healing of chronic venous ulcer with topical sevoflurane | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| BR112022018020A2 (pt) | Formas cristalinas de um composto farmacêutico | |
| MX2023004554A (es) | Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. | |
| CL2021001976A1 (es) | Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular | |
| CL2025000485A1 (es) | Tratamiento combinado con obicetrapib y ezetimiba y composiciones farmacéuticas a dosis fijas | |
| CL2025000581A1 (es) | Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren | |
| AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño | |
| JOP20250311A1 (ar) | مثبطات tyk2 وتركيبات وطرق لها | |
| BR112021025170A2 (pt) | Terapia de combinação | |
| CL2021000444A1 (es) | Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto. | |
| CO2024014215A2 (es) | Formulaciones de inhibidor de tyk2 y métodos para elaborarlas | |
| ZA202005282B (en) | Use of pcsk9 inhibitor for reducing cardiovascular risk | |
| BR112018009476A2 (pt) | regime de dosagem de plasminogênio para cicatrização de ferimentos |